DISEASE INTERCEPTION IN PSORIASIS PATIENTS WITH SUBCLINICAL JOINT INFLAMMATION BY INTERLEUKIN 17 INHIBITION WITH SECUKINUMAB - DATA FROM A PROSPECTIVE OPEN LABEL STUDY

Kamoylafka E, Oliveira ID, Linz C, Lerchen V, Englbrecht M, Simon D, Sticherling M, Rech J, Kleyer A, Schett G, Hueber A (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 77

Pages Range: 199-199

DOI: 10.1136/annrheumdis-2018-eular.3904

Authors with CRIS profile

Matthias Englbrecht Lehrstuhl für Innere Medizin III David Simon Department of Medicine 3 – Rheumatology and Immunology Michael Sticherling Professur für Dermatologie Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology Arnd Kleyer Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III Axel Hueber Department of Medicine 3 – Rheumatology and Immunology

How to cite

APA:

Kamoylafka, E., Oliveira, I.D., Linz, C., Lerchen, V., Englbrecht, M., Simon, D.,... Hueber, A. (2018). DISEASE INTERCEPTION IN PSORIASIS PATIENTS WITH SUBCLINICAL JOINT INFLAMMATION BY INTERLEUKIN 17 INHIBITION WITH SECUKINUMAB - DATA FROM A PROSPECTIVE OPEN LABEL STUDY. (pp. 199-199).

MLA:

Kamoylafka, E., et al. "DISEASE INTERCEPTION IN PSORIASIS PATIENTS WITH SUBCLINICAL JOINT INFLAMMATION BY INTERLEUKIN 17 INHIBITION WITH SECUKINUMAB - DATA FROM A PROSPECTIVE OPEN LABEL STUDY." 2018. 199-199.

BibTeX: Download